Easton Pharmaceuticals, Inc. (EAPH)

[Sage7243]

Easton has the potential to grow much larger! This stock should hit a dime in the new year.

Disclaimer: I have held onto my $EAPH shares for 3 years and recently added much more.


Easton Pharmaceuticals, Inc. (formerly LAM)
(A Development Stage Company)
Financial Statements For Quarter Ended September 30, 2016
Prepared By Management Without Audit
Q3 – September 30, 2016 Page 18



Generic Cancer Drugs: The cancer drugs: Biolyse Pharma Corporation the manufacturer of these drugs
initially entered into an exclusive distribution agreement with BMV Medica, and BMV in turn then
entered into a 50/50 profit split with Easton Pharmaceuticals for the full line of Biolyse-manufactured
drugs beginning with Paclitaxel and docetaxel two of the most-commonly prescribed cancer (oncology)
drugs in use today,- prescribed for breast, lung, colon and several other cancers. Both drugs are generic
with manufacturers from the US, Canada, Mexico, Europe and India vying for a total market of several
Billion dollars for these two drugs.
Easton/BMV’s market is Latin America, where, starting in Mexico, Canadian-manufactured drugs have
an advantage over the Asian-origin drugs, because of NAFTA (North American Free Trade Agreement),
allowing Canadian manufacturers to enter into the lucrative national tenders. In addition Canadianmanufactured
cancer drugs also have a perceived advantage in quality over the Asian-manufactured
counterparts. Easton/BMV have in-licensed the exclusive rights for the full line of Biolyse-manufactured
drugs expected to reach in excess of over 30 drug offerings in the coming five years.